Former FDA counsel: Off-label marketing ban in jeopardy

11/3/2011 | Wall Street Journal, The

Drugmakers have filed a friends-of-the-court brief asserting that marketing drugs for unapproved uses is protected free speech. FDA rules prohibiting off-label marketing are meant to protect patients, says Thomas W. Abrams, director of the FDA's Division of Drug Marketing, Advertising and Communications. Former FDA chief counsel Richard Cooper said a Supreme Court ruling in June on pharmacy records could put the FDA's ban on off-label marketing "in some jeopardy."

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA